A Pilot Randomized Trial of As-Needed Budesonide-Formoterol for Stepping Down Controller Treatment in Moderate Asthma with Complete Remission

被引:1
|
作者
Nakwan, Narongwit [1 ]
Ruklerd, Thidarat [2 ]
Taptawee, Pattarawadee [2 ]
机构
[1] Hat Yai Hosp, Hat Yai Med Educ Ctr, Dept Med, Div Pulmonol, Songkhla 90110, Thailand
[2] Hat Yai Hosp, Dept Nursing, Songkhla, Thailand
关键词
Asthma; Stepping Down; FeNO; Eosinophil; ICS/LABA; NITRIC-OXIDE LEVELS; INHALED CORTICOSTEROIDS; EXHALED AIR; SAMPLE-SIZE; THERAPY; DISEASE; BLOOD; NO;
D O I
10.4046/trd.2022.0038
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The use of low-dose inhaled corticosteroid-formoterol as reliever mono-therapy has recently been recommended in the asthma treatment guidelines. However, the efficacy of this treatment strategy has not yet been determined during the stepping-down period in moderate asthma. This study aimed to evaluate the feasibility of reducing treatment to as-needed budesonide-formoterol (BFM) in moderate asthma with complete remission. Methods: We randomly assigned 31 patients (8 males and 23 females with a mean age of 57.2 years) with complete remission of asthma by inhaled BFM (160/4.5 mu g) twice daily to receive BFM (160/4.5 mu g) as needed (16 patients), or budesonide (BUD) (200 mu g) twice daily (15 patients). The study was an open-label study done for 48 weeks, with the primary outcome as the cumulative percentages of patients with treatment failure (asthma exacerbation or loss of asthma control or lack of satisfaction after using medications) in the two groups. Results: Six patients (42%) using as-needed BFM had treatment failure, as compared with three patients (21.4%) using BUD maintenance (hazards ratio for as-needed BFM, 1.77; 95% confidential interval, 0.44-7.12; p=0.41). The changes in forced expiratory volume in 1 second were -211.3 mL with as-needed BFM versus -97.8 mL with BUD maintenance (difference, 113.5 mL; p=0.75) and the change in fractional exhaled nitric oxide was significantly higher in both groups, at 8.68 parts per billion (ppb) in the as-needed BFM group and 2.5 ppb. in the BUD maintenance group (difference, 6.18 ppb; p=0.049). Conclusion: Compared with BUD maintenance, there were no significant differences in treatment failure rate in patients who received as-needed BFM during the stepping down period in moderate asthma. However, they showed reduced lung function and relapsed airway inflammation. The results are limited by imprecision, and further large RCTs are needed.
引用
收藏
页码:227 / 236
页数:10
相关论文
共 44 条
  • [1] As-Needed Budesonide-Formoterol in Mild Asthma
    Cao, Chao
    Kong, Xue
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 897 - 898
  • [2] As-Needed Budesonide-Formoterol in Mild Asthma Reply
    Bateman, Eric D.
    Reddel, Helen K.
    FitzGerald, J. Mark
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 898 - 898
  • [3] As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma
    Bateman, Eric D.
    Reddel, Helen K.
    O'Byrne, Paul M.
    Barnes, Peter J.
    Zhong, Nanshan
    Keen, Christina
    Jorup, Carin
    Lamarca, Rosa
    Siwek-Posluszna, Agnieszka
    FitzGerald, J. Mark
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (20): : 1877 - 1887
  • [4] As-needed budesonide-formoterol was noninferior to maintenance budesonide for exacerbations in mild asthma
    Stanbrook, Matthew B.
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 169 (06) : JC30 - JC31
  • [5] Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma
    Reddel, Helen K.
    O'Byrne, Paul M.
    FitzGerald, J. Mark
    Barnes, Peter J.
    Zheng, Jinping
    Ivanov, Stefan
    Lamarca, Rosa
    Puu, Margareta
    Alagappan, Vijay K. T.
    Bateman, Eric D.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (08): : 3069 - +
  • [6] AS-NEEDED BUDESONIDE-FORMOTEROL EFFICACY AND SAFETY IN ADOLESCENTS WITH MILD ASTHMA
    Reddel, H.
    Bateman, E.
    Fitzgerald, J.
    Barnes, P.
    Zheng, J.
    Ivanov, S.
    Lamarca, R.
    Puu, M.
    Alagappan, V
    O'Byrne, P.
    [J]. RESPIROLOGY, 2021, 26 : 76 - 76
  • [7] Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma
    Beasley, Richard
    Holliday, Mark
    Reddel, Helen K.
    Braithwaite, Irene
    Ebmeier, Stefan
    Hancox, Robert J.
    Harrison, Tim
    Houghton, Claire
    Oldfield, Karen
    Papi, Alberto
    Pavord, Ian D.
    Williams, Mathew
    Weatherall, Mark
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (21): : 2020 - 2030
  • [8] As-needed budesonide-formoterol for adolescents with mild asthma: Importance of lung function
    Shanthikumar, Shivanthan
    Robinson, Paul D.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (11): : 4178 - 4178
  • [9] Patient experiences of as-needed budesonide-formoterol by Turbuhaler® for treatment of mild asthma; a qualitative study
    Foster, J. M.
    Beasley, R.
    Braithwaite, I
    Harrison, T.
    Holliday, M.
    Pavord, I
    Reddel, H. K.
    [J]. RESPIRATORY MEDICINE, 2020, 175
  • [10] As-needed budesonide-formoterol better controlled mild asthma vs terbutaline, but maintenance budesonide was better
    Stanbrook, Matthew B.
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 169 (06) : JC31 - JC31